Tyr418
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr418  -  Src iso2 (mouse)

Site Information
RLIEDNEyTARQGAK   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448234

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 14 ) , mass spectrometry ( 10 , 11 , 13 ) , mutation of modification site ( 6 , 12 ) , phospho-antibody ( 1 , 2 , 4 , 5 , 6 , 7 , 8 , 9 , 12 , 14 ) , western blotting ( 1 , 2 , 4 , 5 , 6 , 7 , 8 , 9 , 12 , 14 )
Disease tissue studied:
colorectal cancer ( 8 ) , colorectal carcinoma ( 8 ) , lung cancer ( 9 ) , testicular cancer ( 14 ) , diabetes mellitus ( 5 ) , type 2 diabetes ( 5 )
Relevant cell line - cell type - tissue:
3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout] ( 12 ) , 3T3 (fibroblast) [Src (human)] ( 9 ) , BaF3 ('B lymphocyte, precursor') [EGFR (human)] ( 9 ) , BaF3 ('B lymphocyte, precursor') ( 11 , 13 ) , H630 ( 8 ) , HEK293T (epithelial) ( 12 ) , HT-29 (intestinal) ( 8 ) , kidney ( 5 ) , MCT cells (epithelial) ( 5 ) , MEF (fibroblast) ( 4 , 6 ) , mononuclear ( 8 ) , muscle ( 1 ) , myocyte-heart ( 7 ) , P19 (testicular) ( 14 ) , R22 ('muscle, smooth') ( 6 ) , RAW 264.7 (macrophage) ( 2 ) , SW620 (intestinal) ( 8 ) , Swiss 3T3 (fibroblast) ( 12 ) , SYF (fibroblast) ( 6 , 8 ) , vascular smooth muscle cell ('muscle, smooth') ( 6 ) , WiDr (epithelial) ( 8 )

Upstream Regulation
Regulatory protein:
caveolin-1 (mouse) ( 7 ) , PAG (rat) ( 4 )
Phosphatases, in vitro:
PTPRA (human) ( 14 )
Treatments:
anti-MuSK_IgG_ ( 1 ) , cholesterol ( 4 ) , dasatinib ( 8 ) , ischemia/reperfusion ( 7 ) , isoflurane ( 7 ) , naloxone ( 7 ) , PP2 ( 7 ) , SNAP ( 2 ) , SU6656 ( 9 ) , TGF-beta ( 6 ) , thapsigargin ( 12 )

Downstream Regulation
Effects of modification on biological processes:
transcription, induced ( 2 )

References 

1

Ghazanfari N, et al. (2015) Forced expression of muscle specific kinase slows postsynaptic acetylcholine receptor loss in a mouse model of MuSK myasthenia gravis. Physiol Rep 3
26702075   Curated Info

2

Hsieh MY, et al. (2014) The Inducible Nitric-oxide Synthase (iNOS)/Src Axis Mediates Toll-like Receptor 3 Tyrosine 759 Phosphorylation and Enhances Its Signal Transduction, Leading to Interferon-β Synthesis in Macrophages. J Biol Chem 289, 9208-20
24526685   Curated Info

3

Pan Q, et al. (2011) Cdk5 targets active Src for ubiquitin-dependent degradation by phosphorylating Src(S75). Cell Mol Life Sci 68, 3425-36
21442427   Curated Info

4

Oneyama C, et al. (2008) The lipid raft-anchored adaptor protein Cbp controls the oncogenic potential of c-Src. Mol Cell 30, 426-36
18498747   Curated Info

5

Sataranatarajan K, Lee MJ, Mariappan MM, Feliers D (2008) PKCdelta regulates the stimulation of vascular endothelial factor mRNA translation by angiotensin II through hnRNP K. Cell Signal 20, 969-77
18295448   Curated Info

6

Samarakoon R, Higgins SP, Higgins CE, Higgins PJ (2008) TGF-beta1-induced plasminogen activator inhibitor-1 expression in vascular smooth muscle cells requires pp60(c-src)/EGFR(Y845) and Rho/ROCK signaling. J Mol Cell Cardiol 44, 527-38
18255094   Curated Info

7

Patel HH, et al. (2007) Mechanisms of cardiac protection from ischemia/reperfusion injury: a role for caveolae and caveolin-1. FASEB J 21, 1565-74
17272740   Curated Info

8

Serrels A, et al. (2006) Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther 5, 3014-22
17148760   Curated Info

9

Sharma SV, et al. (2006) A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 10, 425-35
17097564   Curated Info

10

Zhou J (2006) CST Curation Set: 1969; Year: 2006; Biosample1/Treatment/Isotope: tissue, brain/untreated/L, Biosample2/Treatment/Isotope: tissue, brain/untreated/H; Disease: -; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: YXp[ST]
Curated Info

11

Goss V (2006) CST Curation Set: 1403; Year: 2006; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

12

Hong M, et al. (2005) Transcriptional regulation of the Grp78 promoter by endoplasmic reticulum stress: role of TFII-I and its tyrosine phosphorylation. J Biol Chem 280, 16821-8
15664986   Curated Info

13

Gu T (2005) CST Curation Set: 700; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

14

den Hertog J, et al. (1993) Receptor protein tyrosine phosphatase alpha activates pp60c-src and is involved in neuronal differentiation. EMBO J 12, 3789-98
7691597   Curated Info